The COVID-19 epidemic has led to new sources of research funding being channeled towards emerging economies. This funding from philanthropists and global governance bodies reflects the fact that emerging economies may not see the peak of the infections for months to come and need support in effectively dealing with the consequences of the pandemic. Understanding the strategic priorities of new funding to properly assess future opportunities for growth is key.

Watch the replay today to hear world renowned speakers, Trevor Mundel, President of Global Health at the Bill & Melinda Gates Foundation, Derek Angus, University of Pittsburgh and James Orbinski, former International President of MSF and Professor at York University, who will provide a critical overview of the New Opportunities & Implications for the Future of Drug Development in Emerging Economies.

Objectives

• Understand the strategic priorities of philanthropic enterprise within global health as it relates to COVID-19;
• Receive an overview of expedited clinical development in emerging economies;
• Harness existing pharmaceutical supply chains in emerging economies;
• Obtain insight into vaccine and drug distribution in emerging economies.

Moderators:

Edward Mills, PhD, FRCP Edin, Principal Scientist, Global Health, Cytel
Craig Rayner, PharmD. President, Integrated Drug Development, Certara

Panelists:

James Orbinski, Dignitas International and York University
Derek Angus, REMAP-CAP and Crown Coronation Trials, and University of Pittsburgh
Trevor Mundel, President, Global Health Division, Bill & Melinda Gates Foundation
Robin Mogg, Bill & Melinda Gates Medical Research Institute